New hope for advanced breast cancer: D-0502 faces off against standard therapy
NCT ID NCT06954961
First seen Apr 03, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study compares a new oral drug, D-0502, to a standard injected drug (fulvestrant) in people with a common type of advanced breast cancer (ER-positive, HER2-negative). The goal is to see if D-0502 can delay cancer growth better than the current treatment. About 640 adults whose cancer has worsened after prior hormone therapy will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Science
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.